RxDoctor Payments Data

Hugh Berckmueller, MD

Ophthalmology · Newport News, VANPI 1093701682

Payments from drug & device makers

$2,222in general payments, 2019–2025

Across 108 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$371
  • Bausch & Lomb Americas Inc.$310
  • Sun Pharmaceutical Industries Inc.$271
  • Alcon$231
  • Tarsus Pharmaceuticals, Inc.$189
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$176
  • plus $673 from 13 others

What the payments were for

  • Food & beverage$2,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,222 in reported general payments places this provider in the 65th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$364,728
Medicare patients
1,373
Services billed
3,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$41,478
LumiganBimatoprost69$38,530
Restasis MultidoseCyclosporine13$17,411
VyzultaLatanoprostene Bunod32$17,336
Travoprost54$13,105
XiidraLifitegrast12$11,567
SimbrinzaBrinzolamide/Brimonidine Tart53$11,235
RocklatanNetarsudil Mesylat/Latanoprost19$7,619
CombiganBrimonidine Tartrate/Timolol14$7,261
Latanoprost308$2,865
Loteprednol Etabonate11$1,620
Tobramycin-DexamethasoneTobramycin/Dexamethasone35$1,522
Prednisolone Acetate47$1,057
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat57$945
Brimonidine Tartrate14$746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$371$104,680131 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$310$28,90344 claims
AlconSimbrinza$231$11,23553 claims
Aerie Pharmaceuticals, Inc.Rocklatan$82$7,61919 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$176$1,62011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →